Legend Biotech (LEGN) Income from Continuing Operations (2019 - 2025)
Legend Biotech (LEGN) posted Income from Continuing Operations of 8400000.0 for Q4 2025, up 78.16% on a QoQ basis from 38457000.0 in Q3 2025, and down 115.33% year-over-year from 54800000.0 in Q4 2024.
Legend Biotech (LEGN) has 7 years of Income from Continuing Operations data on file, last reported at 8400000.0 in Q4 2025.
- In Q4 2025, Income from Continuing Operations fell 115.33% year-over-year to 8400000.0; the TTM figure through Dec 2025 stood at 268417000.0 (down 1269.33% YoY), while the FY2025 annual figure was 268400000.0, down 92.82% from the prior year.
- Income from Continuing Operations rose to 8400000.0 in Q4 2025, from 38457000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 59793000.0 in Q1 2024 and bottomed at 198548000.0 in Q2 2023.
- A 5-year average of 77713033.95 and a median of 88151500.0 in 2021 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations tumbled 32288.91% — and 2024, when it jumped 153.46%.
- Year by year, Income from Continuing Operations stood at 84721000.0 in 2021, then sank by 60.02% to 135570000.0 in 2022, then slipped by 8.29% to 146813994.0 in 2023, then surged by 137.33% to 54800000.0 in 2024, then slumped by 115.33% to 8400000.0 in 2025.
- The last three Income from Continuing Operations figures came in at 8400000.0 (Q4 2025), 38457000.0 (Q3 2025), and 124216000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | -453.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -8.50 Mn |
| Sep 30, 2025 | -38.46 Mn |
| Jun 30, 2025 | -124.22 Mn |
| Mar 31, 2025 | 100.92 Mn |
| Dec 31, 2024 | 54.80 Mn |
| Sep 30, 2024 | -116.45 Mn |
| Jun 30, 2024 | -17.74 Mn |
| Mar 31, 2024 | 59.79 Mn |
| Dec 31, 2023 | -148,806.00 |
| Sep 30, 2023 | -62.78 Mn |
| Jun 30, 2023 | -198.55 Mn |
| Mar 31, 2023 | 112.10 Mn |
| Dec 31, 2022 | -135.57 Mn |
| Sep 30, 2022 | -84.65 Mn |
| Jun 30, 2022 | -192.91 Mn |
| Mar 31, 2022 | -31.96 Mn |
| Dec 31, 2021 | -84.72 Mn |
| Sep 30, 2021 | -124.75 Mn |
| Jun 30, 2021 | -91.58 Mn |
| Mar 31, 2021 | -98,685.00 |
| Dec 31, 2020 | -57.68 Mn |
| Sep 30, 2020 | -67.56 Mn |
| Jun 30, 2020 | -134.88 Mn |
| Mar 31, 2020 | -47.94 Mn |
| Dec 31, 2019 | -59.42 Mn |
| Sep 30, 2019 | -27.79 Mn |
| Jun 30, 2019 | -28.13 Mn |